Logo image of OCUL

OCULAR THERAPEUTIX INC (OCUL) Stock Fundamental Analysis

NASDAQ:OCUL - Nasdaq - US67576A1007 - Common Stock - Currency: USD

7  -0.25 (-3.45%)

After market: 6.9814 -0.02 (-0.27%)

Fundamental Rating

3

Overall OCUL gets a fundamental rating of 3 out of 10. We evaluated OCUL against 194 industry peers in the Pharmaceuticals industry. While OCUL seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, OCUL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

OCUL had negative earnings in the past year.
In the past year OCUL has reported a negative cash flow from operations.
OCUL had negative earnings in each of the past 5 years.
In the past 5 years OCUL always reported negative operating cash flow.
OCUL Yearly Net Income VS EBIT VS OCF VS FCFOCUL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

OCUL has a Return On Assets (-35.55%) which is in line with its industry peers.
OCUL has a Return On Equity of -49.52%. This is comparable to the rest of the industry: OCUL outperforms 57.30% of its industry peers.
Industry RankSector Rank
ROA -35.55%
ROE -49.52%
ROIC N/A
ROA(3y)-27.6%
ROA(5y)-50.4%
ROE(3y)-98.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCUL Yearly ROA, ROE, ROICOCUL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K 2K

1.3 Margins

OCUL's Gross Margin of 90.59% is amongst the best of the industry. OCUL outperforms 94.05% of its industry peers.
OCUL's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for OCUL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.09%
GM growth 5Y3.42%
OCUL Yearly Profit, Operating, Gross MarginsOCUL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OCUL has been increased compared to 1 year ago.
OCUL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for OCUL has been reduced compared to a year ago.
OCUL Yearly Shares OutstandingOCUL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
OCUL Yearly Total Debt VS Total AssetsOCUL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 2.78 indicates that OCUL is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of OCUL (2.78) is better than 71.89% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that OCUL is not too dependend on debt financing.
The Debt to Equity ratio of OCUL (0.19) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 2.78
ROIC/WACCN/A
WACC9.91%
OCUL Yearly LT Debt VS Equity VS FCFOCUL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

OCUL has a Current Ratio of 13.01. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 13.01, OCUL belongs to the best of the industry, outperforming 86.49% of the companies in the same industry.
OCUL has a Quick Ratio of 12.94. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.
OCUL has a Quick ratio of 12.94. This is amongst the best in the industry. OCUL outperforms 86.49% of its industry peers.
Industry RankSector Rank
Current Ratio 13.01
Quick Ratio 12.94
OCUL Yearly Current Assets VS Current LiabilitesOCUL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

OCUL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -44.34%.
OCUL shows a small growth in Revenue. In the last year, the Revenue has grown by 6.45%.
Measured over the past years, OCUL shows a very strong growth in Revenue. The Revenue has been growing by 96.60% on average per year.
EPS 1Y (TTM)-44.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.41%
Revenue 1Y (TTM)6.45%
Revenue growth 3Y49.76%
Revenue growth 5Y96.6%
Sales Q2Q%2.28%

3.2 Future

The Earnings Per Share is expected to grow by 14.36% on average over the next years. This is quite good.
The Revenue is expected to grow by 51.16% on average over the next years. This is a very strong growth
EPS Next Y-2.38%
EPS Next 2Y3.81%
EPS Next 3Y2.5%
EPS Next 5Y14.36%
Revenue Next Year7.42%
Revenue Next 2Y10.46%
Revenue Next 3Y12.7%
Revenue Next 5Y51.16%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
OCUL Yearly Revenue VS EstimatesOCUL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
OCUL Yearly EPS VS EstimatesOCUL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OCUL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OCUL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCUL Price Earnings VS Forward Price EarningsOCUL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCUL Per share dataOCUL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.81%
EPS Next 3Y2.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OCUL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCULAR THERAPEUTIX INC

NASDAQ:OCUL (2/21/2025, 8:00:01 PM)

After market: 6.9814 -0.02 (-0.27%)

7

-0.25 (-3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-06 2025-03-06/amc
Inst Owners87.17%
Inst Owner Change-3.87%
Ins Owners0.8%
Ins Owner Change26.75%
Market Cap1.10B
Analysts86.67
Price Target18.59 (165.57%)
Short Float %7.18%
Short Ratio12.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.08%
Min EPS beat(2)-15.12%
Max EPS beat(2)10.95%
EPS beat(4)1
Avg EPS beat(4)-68.88%
Min EPS beat(4)-258.5%
Max EPS beat(4)10.95%
EPS beat(8)4
Avg EPS beat(8)-31.99%
EPS beat(12)6
Avg EPS beat(12)-14.28%
EPS beat(16)9
Avg EPS beat(16)-31.45%
Revenue beat(2)1
Avg Revenue beat(2)-4.96%
Min Revenue beat(2)-11.78%
Max Revenue beat(2)1.86%
Revenue beat(4)1
Avg Revenue beat(4)-5.89%
Min Revenue beat(4)-11.78%
Max Revenue beat(4)1.86%
Revenue beat(8)3
Avg Revenue beat(8)-3.75%
Revenue beat(12)3
Avg Revenue beat(12)-7.39%
Revenue beat(16)4
Avg Revenue beat(16)-7.42%
PT rev (1m)0%
PT rev (3m)16.31%
EPS NQ rev (1m)-0.17%
EPS NQ rev (3m)-3.63%
EPS NY rev (1m)0%
EPS NY rev (3m)0.01%
Revenue NQ rev (1m)0.2%
Revenue NQ rev (3m)-8.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.91
P/FCF N/A
P/OCF N/A
P/B 3.13
P/tB 3.13
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.39
BVpS2.24
TBVpS2.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.55%
ROE -49.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.59%
FCFM N/A
ROA(3y)-27.6%
ROA(5y)-50.4%
ROE(3y)-98.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.09%
GM growth 5Y3.42%
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.73%
Cap/Sales 2.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.01
Quick Ratio 12.94
Altman-Z 2.78
F-Score4
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)143.18%
Cap/Depr(5y)109.68%
Cap/Sales(3y)6.79%
Cap/Sales(5y)15.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.41%
EPS Next Y-2.38%
EPS Next 2Y3.81%
EPS Next 3Y2.5%
EPS Next 5Y14.36%
Revenue 1Y (TTM)6.45%
Revenue growth 3Y49.76%
Revenue growth 5Y96.6%
Sales Q2Q%2.28%
Revenue Next Year7.42%
Revenue Next 2Y10.46%
Revenue Next 3Y12.7%
Revenue Next 5Y51.16%
EBIT growth 1Y-72.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-91.3%
EBIT Next 3Y-31.94%
EBIT Next 5Y16.58%
FCF growth 1Y-98.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-103.64%
OCF growth 3YN/A
OCF growth 5YN/A